Tu Nguyen Anh Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tu Nguyen Anh Tran has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hao Trong Nguyen
Pham Ngoc Thach University of Medicine
9 shared publications - Nguyen Nhat Pham
Ho Chi Minh City Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam
5 shared publications - Thao Thi Phuong Vu
Ho Chi Minh City Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam
4 shared publications Thuy Thi Phan Nguyen
Ho Chi Minh City Hospital of Dermato‐Venereology Ho Chi Minh City Vietnam
4 shared publicationsEm Van Loi Doan
Ho Chi Minh City Hospital of Dermato‐Venereology Ho Chi Minh City Vietnam
3 shared publications- Nhi Thi Uyen Pham
Ho Chi Minh City Hospital of Dermato-Venereology, Ho Chi Minh City, Vietnam
3 shared publications
Latest Publications
- Open Access
- 25 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72561
Concomitant Sexually Transmitted Infections in Patients With Anal Warts: A Single‐Center, Cross‐Sectional Study in Ho Chi Minh City, Vietnam
Background and Aims: Human papillomavirus infections, with or without lesions, are strongly correlated with anal intercourse. Other sexually transmitted infections (STIs), such as syphilis, gonorrhea, and chlamydia, may be transmitted via anal sex. Polymerase chain reaction (PCR) tests are sensitive and specific for detecting both genital and non‐genital infections. In this study, we aimed to determine the STI rate in genital and non‐genital locations and its relationship with symptoms in patients with anal warts. Methods: We conducted a cross‐sectional study of patients with anal warts who visited the Ho Chi Minh City Hospital of Dermato‐Venereology between October 2022 and November 2023. Patients were interviewed using questionnaires, and swabs from the anal, genital, and oral regions were tested using PCR. Statistical analysis was conducted using χ 2 and Fisher's exact tests, with statistical significance set at p = 0.05. Results: Of the 200 patients with anal warts included in this study, 95.5% tested positive for at least one STI agent in the anorectum (72.5%), pharynx (58.5%), and genitalia (30.0%). Gardnerella vaginalis (71.0%), Mycoplasma hominis (36.5%), and Ureaplasma parvum (22.0%) were the most common PCR‐detected agents. M. hominis dominated the pharyngeal area (33.0%), whereas G. vaginalis dominated both the anorectal (64.5%) and genital areas (10.0%). Rates of presenting symptoms were 54.7% and 68.3% in the pharyngeal and anorectal areas, respectively. Conclusion: The sexually transmitted coinfection rates in patients with anal warts were confirmed, but the symptomatic rates were not. Early diagnosis and treatment are essential. Thus, we propose that PCR tests should be performed in the anorectal, genital, and oral areas in patients with anal warts.
- 25 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72561
Open AccessConcomitant Sexually Transmitted Infections in Patients With Anal Warts: A Single‐Center, Cross‐Sectional Study in Ho Chi Minh City, Vietnam
Background and Aims: Human papillomavirus infections, with or without lesions, are strongly correlated with anal intercourse. Other sexually transmitted infections (STIs), such as syphilis, gonorrhea, and chlamydia, may be transmitted via anal sex. Polymerase chain reaction (PCR) tests are sensitive and specific for detecting both genital and non‐genital infections. In this study, we aimed to determine the STI rate in genital and non‐genital locations and its relationship with symptoms in patients with anal warts. Methods: We conducted a cross‐sectional study of patients with anal warts who visited the Ho Chi Minh City Hospital of Dermato‐Venereology between October 2022 and November 2023. Patients were interviewed using questionnaires, and swabs from the anal, genital, and oral regions were tested using PCR. Statistical analysis was conducted using χ 2 and Fisher's exact tests, with statistical significance set at p = 0.05. Results: Of the 200 patients with anal warts included in this study, 95.5% tested positive for at least one STI agent in the anorectum (72.5%), pharynx (58.5%), and genitalia (30.0%). Gardnerella vaginalis (71.0%), Mycoplasma hominis (36.5%), and Ureaplasma parvum (22.0%) were the most common PCR‐detected agents. M. hominis dominated the pharyngeal area (33.0%), whereas G. vaginalis dominated both the anorectal (64.5%) and genital areas (10.0%). Rates of presenting symptoms were 54.7% and 68.3% in the pharyngeal and anorectal areas, respectively. Conclusion: The sexually transmitted coinfection rates in patients with anal warts were confirmed, but the symptomatic rates were not. Early diagnosis and treatment are essential. Thus, we propose that PCR tests should be performed in the anorectal, genital, and oral areas in patients with anal warts.
- 8 July 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 109-111
Pachyonychia congenita: A father and son with a novel variant in the KRT16 gene
This study underscores the significance of identifying the clinical manifestations of pachyonychia congenita (PC) and emphasizes the patterns of genetic inheritance. A 12‐month‐old boy presented with a “white hairy tongue” and, following a comprehensive evaluation, was diagnosed with PC. His father exhibited similar symptoms. Genetic testing revealed a KRT16 pathogenic variant (c.616 T > G) in both the patient and his father, marking it as a novel variant in the PC literature. This case contributes to a broader understanding of PC's genetic diversity and its clinical presentations.
- 8 July 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 109-111
Pachyonychia congenita: A father and son with a novel variant in the KRT16 gene
This study underscores the significance of identifying the clinical manifestations of pachyonychia congenita (PC) and emphasizes the patterns of genetic inheritance. A 12‐month‐old boy presented with a “white hairy tongue” and, following a comprehensive evaluation, was diagnosed with PC. His father exhibited similar symptoms. Genetic testing revealed a KRT16 pathogenic variant (c.616 T > G) in both the patient and his father, marking it as a novel variant in the PC literature. This case contributes to a broader understanding of PC's genetic diversity and its clinical presentations.
- Open Access
- 21 May 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (10) , 3210-3221
Simultaneous versus sequential fractional CO2 laser and subcision combination for management of post‐acne atrophic scars: A split‐face comparative study
Background: A combination of fractional CO2 laser and subcision is usually employed for the treatment of post‐acne atrophic scars. However, the efficacy and safety of both simultaneous and sequential combination therapies should be explored.Aims: To compare the efficacy and safety of simultaneous and sequential fractional CO2 laser and subcision combination therapies for post‐acne atrophic scars.Patients and Methods: This single‐blind, split‐face clinical trial included 34 patients with post‐acne atrophic scars at our institution. Each patient underwent three sessions of subcision combined with fractional CO2 laser, with a 1‐month interval between each session. The left side of the face was treated with simultaneous combination therapy, whereas the right side was treated with sequential combination therapy. Treatment efficacy was assessed at 4, 8, and 12 weeks; and 3 and 6 months after the last session.Results: Simultaneous and sequential treatments demonstrated comparable efficacy. Regarding the adverse events, the side of the face undergoing simultaneous treatment experienced longer swelling duration, higher pain levels during laser treatment, and shorter downtime.Conclusions: Despite the longer swelling time and higher pain levels during laser treatment in the simultaneous treatment side, the effectiveness and satisfaction level of the CO2 fractional laser and subcision for treatment of the acne scars were comparable between the two combinations, with a shorter downtime for the simultaneous than for the sequential combination therapy.
- 21 May 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (10) , 3210-3221
Open AccessSimultaneous versus sequential fractional CO2 laser and subcision combination for management of post‐acne atrophic scars: A split‐face comparative study
Background: A combination of fractional CO2 laser and subcision is usually employed for the treatment of post‐acne atrophic scars. However, the efficacy and safety of both simultaneous and sequential combination therapies should be explored.Aims: To compare the efficacy and safety of simultaneous and sequential fractional CO2 laser and subcision combination therapies for post‐acne atrophic scars.Patients and Methods: This single‐blind, split‐face clinical trial included 34 patients with post‐acne atrophic scars at our institution. Each patient underwent three sessions of subcision combined with fractional CO2 laser, with a 1‐month interval between each session. The left side of the face was treated with simultaneous combination therapy, whereas the right side was treated with sequential combination therapy. Treatment efficacy was assessed at 4, 8, and 12 weeks; and 3 and 6 months after the last session.Results: Simultaneous and sequential treatments demonstrated comparable efficacy. Regarding the adverse events, the side of the face undergoing simultaneous treatment experienced longer swelling duration, higher pain levels during laser treatment, and shorter downtime.Conclusions: Despite the longer swelling time and higher pain levels during laser treatment in the simultaneous treatment side, the effectiveness and satisfaction level of the CO2 fractional laser and subcision for treatment of the acne scars were comparable between the two combinations, with a shorter downtime for the simultaneous than for the sequential combination therapy.
- Open Access
- 29 January 2024
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (3) , 9888
Diverse clinical manifestations of acquired vulvar lymphangioma: a report of five cases in Vietnamese women
Acquired vulvar lymphangioma (AVL) is a rare but important condition that requires prompt diagnosis and appropriate management to alleviate symptoms and prevent complications. AVL can erupt locally as isolated or clustered lesions which range from translucent, fluid-filled vesicles to smooth, flesh-colored papules or nodules that exude serous or crystalline liquid spontaneously or after trauma. Clinically, it can also be asymptomatic. However, symptoms are commonly accompanied by vulvar itching, burning, soreness, or unpleasant discharge. Here, we report a case series of five Vietnamese patients with AVL with diverse clinical features.
- 29 January 2024
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (3) , 9888
Open AccessDiverse clinical manifestations of acquired vulvar lymphangioma: a report of five cases in Vietnamese women
Acquired vulvar lymphangioma (AVL) is a rare but important condition that requires prompt diagnosis and appropriate management to alleviate symptoms and prevent complications. AVL can erupt locally as isolated or clustered lesions which range from translucent, fluid-filled vesicles to smooth, flesh-colored papules or nodules that exude serous or crystalline liquid spontaneously or after trauma. Clinically, it can also be asymptomatic. However, symptoms are commonly accompanied by vulvar itching, burning, soreness, or unpleasant discharge. Here, we report a case series of five Vietnamese patients with AVL with diverse clinical features.
- Open Access
- 17 November 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (12) , 3193-3208
Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study
Introduction Psoriasis is a multi-faceted, immune-mediated inflammatory disease associated with a wide range of comorbidities. Real-world data on treatment patterns, comorbidities, and economic burden in patients with psoriasis are needed for comprehensive patient care in Vietnam. Methods A retrospective chart review study was conducted using secondary data extracted from patients’ medical records of two hospitals in Vietnam, with the aim of identifying adult patients with a confirmed diagnosis of psoriasis. The index date was defined as the date of first diagnosis between 1 January 2020 and 31 October 2021. Sociodemographic factors, disease characteristics, comorbidities, medication usage, drug survival, and medication costs were analyzed. Results A total of 661 patients were identified (mean ± standard deviation [SD] age 43.5 ± 14.8 years). The most prevalent comorbidity was dyslipidemia (49.6% of patients), followed by hypertension (23.4%), and psoriatic arthritis (10.4%). In total, 44% of patients received biologic therapies. Overall, 66.7% and 54.3% of patients receiving biologic and non-biologic therapies, respectively, had ≥ 1 comorbidity. Only 23.2% of patients with psoriasis-related comorbidities stopped therapy with biologics. Biologics had a longer retention time (17.0 months) than non-biologics (6.0 months) in patients with comorbidities. Patients with comorbidities had significantly higher total annual healthcare costs than those without comorbidities (in US dollars: USD901 vs. USD304; p < 0.001), mainly due to the relatively higher costs associated with the use of biologics. Conclusion Patients with psoriasis in Vietnam experience a high disease and economic burden due to comorbidities. Evidence from this real-world study supports the need for routine monitoring of and an appropriate treatment course for psoriasis-related comorbidities.
- 17 November 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (12) , 3193-3208
Open AccessComorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study
Introduction Psoriasis is a multi-faceted, immune-mediated inflammatory disease associated with a wide range of comorbidities. Real-world data on treatment patterns, comorbidities, and economic burden in patients with psoriasis are needed for comprehensive patient care in Vietnam. Methods A retrospective chart review study was conducted using secondary data extracted from patients’ medical records of two hospitals in Vietnam, with the aim of identifying adult patients with a confirmed diagnosis of psoriasis. The index date was defined as the date of first diagnosis between 1 January 2020 and 31 October 2021. Sociodemographic factors, disease characteristics, comorbidities, medication usage, drug survival, and medication costs were analyzed. Results A total of 661 patients were identified (mean ± standard deviation [SD] age 43.5 ± 14.8 years). The most prevalent comorbidity was dyslipidemia (49.6% of patients), followed by hypertension (23.4%), and psoriatic arthritis (10.4%). In total, 44% of patients received biologic therapies. Overall, 66.7% and 54.3% of patients receiving biologic and non-biologic therapies, respectively, had ≥ 1 comorbidity. Only 23.2% of patients with psoriasis-related comorbidities stopped therapy with biologics. Biologics had a longer retention time (17.0 months) than non-biologics (6.0 months) in patients with comorbidities. Patients with comorbidities had significantly higher total annual healthcare costs than those without comorbidities (in US dollars: USD901 vs. USD304; p < 0.001), mainly due to the relatively higher costs associated with the use of biologics. Conclusion Patients with psoriasis in Vietnam experience a high disease and economic burden due to comorbidities. Evidence from this real-world study supports the need for routine monitoring of and an appropriate treatment course for psoriasis-related comorbidities.
- Open Access
- 3 September 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (11) , 2927
Correction to: Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
- 3 September 2023
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (11) , 2927
Open AccessCorrection to: Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
- Open Access
- 6 December 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (2) , 465-476
Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO. Methods This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months. Results In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate. Conclusion Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance.
- 6 December 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 13 (2) , 465-476
Open AccessLong-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
Introduction Psoriasis (PsO), an immune-mediated inflammatory skin disorder, has substantial negative impact on patients’ quality of life. Secukinumab, an approved treatment for moderate-to-severe plaque PsO, has an established long-term efficacy and safety profile. This study aims to provide real-world evidence of long-term effectiveness and retention rate of secukinumab in Vietnamese patients with PsO. Methods This retrospective, observational study collected medical records of adult patients with moderate-to-severe PsO receiving secukinumab treatment from Ho Chi Minh City Hospital of Dermato-Venereology. The primary objective was to evaluate secukinumab effectiveness in PsO as measured by 75% improvement in psoriasis area and severity index (PASI 75) at month 12. Secondary objectives were PASI 90/100, absolute PASI ≤ 3 and ≤ 5, Dermatology Life Quality Index (DLQI), and retention rate over 48 months. Results In total, 232 patients with moderate-to-severe PsO met inclusion criteria; 68.1% were male, with median age and age of onset of 39 and 27.5 years, respectively. Median time from onset of PsO to secukinumab treatment was 120 months, 95.3% were prior biologics/disease-modifying antirheumatic drugs naive and 41.4% received concomitant therapies for PsO; 82.3% had national insurance coverage. At month 12, 93.9% of patients achieved PASI 75 (primary endpoint); 80.2/56.9% achieved PASI 90/100; 91.4 and 84.8% patients achieved absolute PASI ≤ 5 and ≤ 3, respectively. The response was sustained over 48 months, with 91.9%/78.0%/52.0% of patients achieving PASI 75/90/100, 89.5% and 82.1% patients achieving absolute PASI ≤ 5 and ≤ 3, respectively. At month 12, 61.4% of patients achieved DLQI 0/1 which was sustained up to month 48 (69.2%). Secukinumab adherence rate of 84.9% at month 12 dropped to 34.2% at month 48. Patients receiving concomitant therapy and national insurance showed higher adherence rate. Conclusion Secukinumab demonstrated long-term effectiveness in real-world Vietnamese patients with moderate-to-severe PsO, with treatment adherence being higher in patients having concomitant therapies and national insurance.
- 26 May 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15590
New onset of psoriasis following COVID ‐19 vaccination
The cutaneous side effects of COVID‐19 vaccines are being studied and their immunogenicity is most likely linked to the pathophysiology of psoriasis. Although uncommon, several cases of exacerbation and new onset of psoriasis have been reported globally after vaccination. To contribute to the literature on this intriguing topic, we present three cases of de novo psoriasis in adult patients following COVID‐19 vaccination. Our observations and a literature review show that this occurrence is independent of the type and brand of vaccines.
- 26 May 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (8) , e15590
New onset of psoriasis following COVID ‐19 vaccination
The cutaneous side effects of COVID‐19 vaccines are being studied and their immunogenicity is most likely linked to the pathophysiology of psoriasis. Although uncommon, several cases of exacerbation and new onset of psoriasis have been reported globally after vaccination. To contribute to the literature on this intriguing topic, we present three cases of de novo psoriasis in adult patients following COVID‐19 vaccination. Our observations and a literature review show that this occurrence is independent of the type and brand of vaccines.
- Open Access
- 13 September 2021
- Published by Hindawi Limited in Case Reports in Genetics
- Vol. 2021, 1-5
The First Vietnamese Patient of LEOPARD Syndrome due to a PTPN11 Mutation: A Case Report and Review of the Literature
LEOPARD syndrome is a rare congenital anomaly that involves several organs. Patients with this syndrome develop multiple lentigines resembling a leopards hide. LEOPARD is an acronym of the major features constituting the syndrome including lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary valve stenosis, anomalies of genitalia, retardation of growth, and deafness. The syndrome is rare, and only 200 cases have been reported yet worldwide. We present the case of an 8-year-old female patient who visited the Ho Chi Minh City Hospital of Dermato-Venereology because of multiple brownish-black dots on her face and body. On examination, she also showed abnormalities in the maxillofacial bones, vertebrae, shoulders, sternum, and teeth, as well as deaf-mutism and growth retardation, which are typical of LEOPARD syndrome. Genetic analysis revealed a PTPN11 gene mutation in this case. To the best of our knowledge, this is the first case of LEOPARD syndrome reported in Vietnam.
- 13 September 2021
- Published by Hindawi Limited in Case Reports in Genetics
- Vol. 2021, 1-5
Open AccessThe First Vietnamese Patient of LEOPARD Syndrome due to a PTPN11 Mutation: A Case Report and Review of the Literature
LEOPARD syndrome is a rare congenital anomaly that involves several organs. Patients with this syndrome develop multiple lentigines resembling a leopards hide. LEOPARD is an acronym of the major features constituting the syndrome including lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary valve stenosis, anomalies of genitalia, retardation of growth, and deafness. The syndrome is rare, and only 200 cases have been reported yet worldwide. We present the case of an 8-year-old female patient who visited the Ho Chi Minh City Hospital of Dermato-Venereology because of multiple brownish-black dots on her face and body. On examination, she also showed abnormalities in the maxillofacial bones, vertebrae, shoulders, sternum, and teeth, as well as deaf-mutism and growth retardation, which are typical of LEOPARD syndrome. Genetic analysis revealed a PTPN11 gene mutation in this case. To the best of our knowledge, this is the first case of LEOPARD syndrome reported in Vietnam.